© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
September 20, 2022
At the recent Women in Ophthalmology Summer Symposium, held in Monterey, California, Cathleen M. McCabe, MD, outlined how pilocarpine HCl Ophthalmic Solution 1.25%, the first and only FDA-approved eye drop to treat presbyopia could offer an opportunity for patients looking for spectacle independence.
August 26, 2022
The IOL has a hybrid design that combines the benefits of central extended depth-of-focus technology and multifocal technology that provides a continuous range of high-quality vision ranging from distance and intermediate and near vision to about 12 to 14 inches.
July 29, 2022
The Grail study finds the device can offer positive outcomes for patients.
May 11, 2022
Catching up after ASCRS 2022, Ora's Caitlin Black, senior director and therapeutic area head of medical devices, talks about the next generation of ophthalmic device therapies and diagnostics, clinical trial updates and new innovations that are most exciting for presbyopia treatment.
May 11, 2022
The companies will collaborate to commercialize therapeutic option in Greater China, South Korea and Select Southeast Asian Markets for the treatment of presbyopia, expanding access to long-acting, presbyopia-correcting eye drops for approximately 600 million patients.
May 03, 2022
Technical details, communication style key to presbyopia-correcting IOL journey.
April 28, 2022
George Waring, MD, discusses the findings of a retrospective study on Allergan’s AGN-190584 for the treatment of presbyopia.
April 26, 2022
Ben Bergo, CEO of Visus Therapeutics, gives a company update on the company's presented phase 2 data, and what's next in the pipeline.
April 25, 2022
In a presentation at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting, Marjan Farid, MD, ABO, and Preeya K. Gupta, MD, offered details of clinical trials for CSF-1 ophthalmic solution, a presbyopia eye drop candidate. Results showed that nearly half of the participants treated with CSF-1 achieved a 3-line or more increase in the distance-corrected near visual acuity an hour after drop instillation on day 15.
Visus Therapeutics expands ophthalmic drug development portfolio with acquisition of ViewPoint Therapeutics' assets
The survey, from The Larry A. Greene Center and the Primary Care Collaborative, found that the COVID-19 pandemic has had an adverse impact on the well-being of physicians.
Myze launches for platform to engage 1 million dry eye patients by 2025: How Do Your Eyes Feel?